hrp0098rfc6.6 | Fat, Metabolism and Obesity 1 | ESPE2024

Potential role of aspg methylation as a biomarker of childhood obesity

Gomez-Vilarrubla Ariadna , Niubó-Pallàs Maria , Mas-Parés Berta , Carreras-Badosa Gemma , Bonmatí Alexandra , Martinez-Calcerrada Jose-María , de Zegher Francis , Ibañez Lourdes , López-Bermejo Abel , Bassols Judit

Introduction: A global methylation array previously performed by our group in placental samples revealed a nominal association of a CpG site (CpGs) located at chr14:104552209 in the ASPG (Asparaginase) gene with childhood obesity. ASPG (Asparaginase) when used to treat haematologic neoplasms can cause liver steatosis. Asparaginase reduces asparagine blood levels, which is known to promote the development of metabolic syndrome and obesity in both child...

hrp0095fc5.2 | Adrenals and HPA Axis | ESPE2022

Thioredoxin Reductase 2 (TXNRD2) Variant As A Cause Of Micropenis, Undescended Testis And Selective Glucocorticoid Deficiency

Patjamontri Supitcha , Lucas-Herald Angela , McMillan Martin , Prasad Rathi , Metherell Louise , McGowan Ruth , Tobias Edward , Faisal Ahmed S.

Introduction: The molecular aetiology of familial glucocorticoid deficiency (FGD) is very heterogeneous. A recent report of a genetic variant in TXNRD2, the gene encoding thioredoxin reductase Type 2, in a South Asian kindred with FGD suggests that the maintenance of redox balance may be critical for adrenocortical function. We present the second report of an individual from another south Asian family harbouring a different pathological variant in <em...

hrp0095fc11.3 | Late Breaking | ESPE2022

Dasiglucagon Significantly Reduces Requirement for Intravenous Glucose in Children with Congenital Hyperinsulinism ages 7 Days to 12 Months

De Leon Diva D. , Banerjee Indraneel , M Kendall David , Birch Sune , Bøge Eva , Ivkovic Jelena , Thornton Paul S

Background: Congenital hyperinsulinism (CHI) is a rare disease affecting neonates, infants, and children. CHI is characterized by dysregulated insulin secretion resulting in severe recurrent hypoglycemia. Early treatment is necessary to limit the risk of neurologic and developmental sequelae. Current treatment options are limited and inadequate. Dasiglucagon (DASI) is a glucagon analog suitable for continuous subcutaneous infusion which has been shown to raise...

hrp0095rfc11.1 | Late Breaking | ESPE2022

Six-months of treatment with exenatide improves glycemic control, but does not affect endogenous intact GLP-1 concentrations in adolescents with obesity

Stenlid Rasmus , Y. Cerenius Sara , K. Aydin Banu , S. Gjessing Erik , Manell Hannes , Weghuber Daniel , Forslund Anders , Bergsten Peter

Introduction: When used to treat obesity, glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RA) improve both BMI and metabolic health. Liraglutide is approved by both the EMA and FDA for the treatment of pediatric obesity, from 12 years and older. However, 26 weeks after discontinuation of liraglutide, the weight lost during treatment is regained. Prolonged exogenous stimulation of hormone-specific receptors may influence endogenous hormonal regulation. ...

hrp0095p1-314 | Growth and Syndromes | ESPE2022

Klinefelter Syndrome: Clinical Spectrum Based on 21 years experience of a Pediatric Endocrinology Unit

Filipa Pinto Oliveira Joana , Cardoso Sandra , João Oliveira Maria , Freitas Joana , Ribeiro Luís , Mendes Catarina , Borges Teresa

Background and Aims: Klinefelter syndrome (KS) is the most common chromosomal abnormality in men, but because of its highly variable phenotype and clinical unawareness, it remains largely under-diagnosed. Cardinal features include tall stature, gynecomastia, hypergonadotropic hypogonadism, azoospermia and infertility. Learning and behavioral problems are also common. Testosterone replacement therapy (TRT) helps to prevent or ameliorate many of the comorbiditie...

hrp0095p1-378 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2022

Assessment Of External Genitalia Change Over Time In Boys With XY Disorder Of Sex Development (DSD)

Alimussina Malika , Kraria Loubna , McGowan Ruth , Steven Mairi , Lee Boma , Flett Martyn , O’Toole Stuart , Faisal Ahmed S

Introduction: The external masculinisation score (EMS) has been utilised as an objective numerical description of the external genitalia in undermasculinised patients with DSD in several studies. However, data on longitudinal change in EMS in the routine clinical setting are lacking.Objectives: To determine the longitudinal change in EMS and its determinants in a cohort of boys with XY DSD in one specialist centre.<p...

hrp0095lb13 | Late Breaking | ESPE2022

Residual C-peptide secretion and glycemic control in pediatric patients with Diabetes Mellitus type 1

João Gaia Maria , Pedrosa Inês , Adriana Rangel Maria , Arménia Campos Rosa , Luísa Leite Ana

Introduction: Residual C-peptide secretion has been associated with less hypoglycemic events and lower glycemic variability in patients with Diabetes Mellitus type 1 (DM1), primarily in adults. The authors sought to evaluate the association between residual C-peptide secretion in pediatric patients with DM1 and glycemic control variables.Methods: Cross-sectional study conducted in a level II hospital, in DM1 patients you...

hrp0095p2-11 | Adrenals and HPA Axis | ESPE2022

Differences in The Management of Classic Childhood Congenital Adrenal Hyperplasia in Spain According to A Patients Association

Murillo-Vallés , Valls-Llussà Aina , Martinez-Couselo Silvia , Salinas-Vert Isabel , de Diego-Suarez Marta Marta

Objective: Despite published guidelines, there is no single approach to management in congenital adrenal hyperplasia (CAH). The objective of the study was to explore the variations in treatment for CAH in Spain.Material and methods: A retrospective study in a single center was done analyzing the data provided by patients and relatives through the Spanish Association of CAH from a online survey of 25 questions. It was dif...

hrp0092fc14.2 | GH and IGF2 | ESPE2019

Pubertal Onset in 1572 Girls with Short, Normal and Tall Stature: Associations to Height, Serum IGF-I and PAPP-A2 Genotypes

Upners Emmie N , Busch Alexander S. , Almstrup Kristian , Petersen Jørgen Holm , Main Katharina , Jensen Rikke Beck , Juul Anders

Background: Sexual maturation is closely linked to growth, suggesting common pathways between the reproductive development and the growth hormone/insulin-like growth factor-I (GH/IGF-I) axis. IGF-I bioavailability is regulated by Pregnancy associated plasma protein-A (PAPP-A), Pregnancy associated plasma protein-A2 (PAPP-A2) and Stanniocalcin 2 (STC2). A large genome-wide association study (GWAS) identified PAPP-A, PAPP-A2 and STC2 to represent loci strongly a...

hrp0092fc14.5 | GH and IGF5 | ESPE2019

OOnce-weekly Somapacitan vs Daily Growth Hormone (Norditropin®) in Childhood Growth Hormone Deficiency: One-year Results from a Randomised Phase 2 Trial

Sävendahl Lars , Battelino Tadej , Horikawa Reiko , Juul Rasmus Vestergaard , Rasmussen Michael Højby , Saenger Paul

Daily injections are required for human growth hormone (GH) replacement therapy. Somapacitan is a long-acting GH derivative being developed for once-weekly dosing in adults and children using a proven protraction method, currently successfully in use to extend the half-life of insulin and glucagon-like peptide 1.To evaluate the efficacy and safety of three different once-weekly somapacitan doses compared with Norditropin®, a daily GH, ove...